Trusted Resources: Education
Scientific literature and patient education texts
Enzyme Replacement Therapy With Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
source: International journal of molecular sciences
authors: Giugliani R,Martins AM,Okuyama T,Eto Y,Sakai N,Nakamura K,Morimoto H,Minami K,Yamamoto T,Yamaoka M,Ikeda T,So S,Tanizawa K,Sonoda H,Schmidt M,Sato Ysummary/abstract:
Enzyme replacement therapy (ERT) improves somatic manifestations in mucopolysaccharidoses (MPS). However, because intravenously administered enzymes cannot cross the blood-brain barrier (BBB), ERT is ineffective against the progressive neurodegeneration and resultant severe central nervous system (CNS) symptoms observed in patients with neuronopathic MPS. Attempts to surmount this problem have been made with intrathecal and intracerebroventricular ERT in order to achieve CNS effects, but the burdens on patients are inimical to long-term administrations. However, since pabinafusp alfa, a human iduronate-2-sulfatase fused with a BBB-crossing anti-transferrin receptor antibody, showed both central and peripheral efficacy in a mouse model, subsequent clinical trials in a total of 62 patients with MPS-II (Hunter syndrome) in Japan and Brazil substantiated this dual efficacy and provided an acceptable safety profile. To date, pabinafusp alfa is the only approved intravenous ERT that is effective against both the somatic and CNS symptoms of patients with MPS-II. This article summarizes the previously obtained preclinical and clinical evidence related to the use of this drug, presents latest data, and discusses the preclinical, translational, and clinical challenges of evaluating, ameliorating, and preventing neurodegeneration in patients with MPS-II.organization: Department of Genetics, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre 90040-060, Brazil.
UPMC Children’s Hospital of Pittsburgh – Center for Rare Disease TherapyHurler syndrome (mucopolysaccharidosis t...
Golgi Requires a New Casting in the Screenplay of Mucopolysaccharidosis II CytopathologyLysosome (L), a hydrolytic compartment o...
Impact of the COVID-19 Pandemic on the Standard of Care for Patients With Lysosomal Storage Diseases: A Survey of He...The impact of the COVID-19 pandemic on t...
Analysis of Cognitive Ability and Adaptive Behavior Assessment Tools Used in an Observational Study of Patients With...Mucopolysaccharidosis II (MPS II) is a r...
Hunter Syndrome (MPS II): An Uncommon Combination of Childhood Complaintshttps://www.youtube.com/watch?v=7kBGEYAF...
Evaluation of the Long-Term Treatment Effects of Intravenous Idursulfase in Patients With Mucopolysaccharidosis II (...Mucopolysaccharidosis II (MPS II; Hunter...
Hunter Syndrome: OverviewHunter syndrome is a very rare, inherite...